Afferent Pharmaceuticals Expands Executive Leadership Team With Appointments of Prabha N. Ibrahim, PhD, as Chief Technology Officer and Michelle Carpenter, JD, RAC, as Vice President, Regulatory Affairs and Project Management
San Mateo, CA – November 19, 2015 – Afferent Pharmaceuticals, a leader in the development of small molecule compounds for the treatment of poorly managed and common neurogenic disorders, today announced the appointments of Prabha N. Ibrahim, Ph.D., as chief technology officer and Michelle Carpenter, J.D., RAC, as vice president of regulatory affairs and project management. The Company is expanding its executive team as it advances its lead program and first-in-class drug candidate, AF-219, to late-stage clinical development and potential registration. AF-219 is a selective, non-narcotic, and orally administered P2X3 antagonist that targets the mechanism by which certain nerve fibers become hyper-sensitized and can lead to chronic and debilitating symptoms.
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.